Dulaglutide vs Semaglutide
Dulaglutide (GLP-1 receptor agonist)
A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.
Semaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
| Attribute | Dulaglutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Trulicity) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~5 days | ~7 days |
| Molecular weight | ~59,700 Da | 4,113.6 Da |
| Mechanism | Activates the GLP-1 receptor to enhance glucose-dependent insulin release, suppress glucagon, and slow gastric emptying. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Legal status (US) | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Dulaglutide and Semaglutide?
Dulaglutide: A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Dulaglutide or Semaglutide?
Dulaglutide is rated Strong and Semaglutide is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Dulaglutide and Semaglutide FDA-approved?
Dulaglutide: FDA-approved (Trulicity). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.